Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
OCTOBER 5, 2023
Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee (ODAC) gathered Thursday to weigh the merits of the cancer med’s phase 3 cli | Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee gathered Thursday to weigh the (..)
237 
Let's personalize your content